Zydus launches cancer biosimilar nivolumab at steep discount
The launch follows a Delhi High Court nod allowing sales of the cancer drug biosimilar ahead of patent expiry in May 2026.
The launch follows a Delhi High Court nod allowing sales of the cancer drug biosimilar ahead of patent expiry in May 2026.
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
